Abstract
In heart failure (HF) patients, current European Society of Cardiology (ESC) guidelines recommend the use of three loop diuretics (furosemide, torasemide, bumetanide) in order to not only reduce HF hospitalizations but also improve symptoms and exercise capacity in patients with signs and/or symptoms of congestion. In addition, for the first time in hypertensive patients, European Society of Hypertension (ESH) guidelines recommend the use of torasemide. This review aimed to summarize the mode of action of loop diuretics, to present their pharmacokinetic characteristics, and to discuss their place in the management of arterial hypertension and heart failure, with special emphasis however on torasemide.
Keywords: Loop diuretics, torasemide, heart failure, hypertension, thiazide diuretics, furosemide, bumetanide.
Current Pharmaceutical Design
Title:Torasemide in Hypertension and Heart Failure: Re-inventing Loop Diuretic Therapy?
Volume: 27 Issue: 23
Author(s): Athanasios Manolis, Manolis Kallistratos*Michael Doumas
Affiliation:
- Cardiology Department, Asklepeion Hospital, Athens,Greece
Keywords: Loop diuretics, torasemide, heart failure, hypertension, thiazide diuretics, furosemide, bumetanide.
Abstract: In heart failure (HF) patients, current European Society of Cardiology (ESC) guidelines recommend the use of three loop diuretics (furosemide, torasemide, bumetanide) in order to not only reduce HF hospitalizations but also improve symptoms and exercise capacity in patients with signs and/or symptoms of congestion. In addition, for the first time in hypertensive patients, European Society of Hypertension (ESH) guidelines recommend the use of torasemide. This review aimed to summarize the mode of action of loop diuretics, to present their pharmacokinetic characteristics, and to discuss their place in the management of arterial hypertension and heart failure, with special emphasis however on torasemide.
Export Options
About this article
Cite this article as:
Manolis Athanasios , Kallistratos Manolis *, Doumas Michael , Torasemide in Hypertension and Heart Failure: Re-inventing Loop Diuretic Therapy?, Current Pharmaceutical Design 2021; 27 (23) . https://dx.doi.org/10.2174/1381612827666210406142933
DOI https://dx.doi.org/10.2174/1381612827666210406142933 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Cnidaria in Drug Discovery. A Review on CNS Implications and New Perspectives
Recent Patents on CNS Drug Discovery (Discontinued) Metal Complexes, their Cellular Targets and Potential for Cancer Therapy
Current Pharmaceutical Design An Algorithm to Classify Amino Acid Sequences into Protein Groups of Bothrops jararacussu Venomous Gland
Protein & Peptide Letters Pulmonary Hypertension: Types and Treatments
Current Cardiology Reviews Microcirculation in Hypertension: An Update on Clinical Significance and Therapy
Current Vascular Pharmacology Neuroprotective Effects of Drug-Induced Therapeutic Hypothermia in Central Nervous System Diseases
Current Drug Targets Protein O-GlcNAcylation: A Critical Regulator of the Cellular Response to Stress
Current Signal Transduction Therapy Near Infrared Spectroscopy in Healthy Preterm and Term Newborns: Correlation with Gestational Age and Standard Monitoring Parameters
Current Neurovascular Research Hydrolyzates of Silkworm Pupae (Bombyx Mori) Protein is a New Source of Angiotensin I-Converting Enzyme Inhibitory Peptides(ACEIP)
Current Pharmaceutical Biotechnology Vasorelaxant and Antihypertensive Effects of <i>Mentha pulegium</i> L. in Rats: An In vitro and In vivo Approach
Endocrine, Metabolic & Immune Disorders - Drug Targets The Oxygen Therapy
Current Medicinal Chemistry Management of Acute Aluminum Phosphide Poisoning: Has Anything Changed?
Drug Metabolism Letters Adverse Drug Reactions: Trends in a Tertiary Care Hospital
Current Drug Safety Silent Cerebral Damage in Hypertension
Current Hypertension Reviews Nutrigenomics and its Impact on Life Style Associated Metabolic Diseases
Current Genomics Amlodipine (150 mg) Poisoning: A Case Study
Current Drug Safety A<sub>3</sub> Adenosine Receptor: A Plausible Therapeutic Target for Cardio-Protection in Diabetes
Recent Patents on Cardiovascular Drug Discovery Telomere/Telomerase System: A New Target of Statins Pleiotropic Effect?
Current Vascular Pharmacology Effects of ACE-Inhibitors and Angiotensin Receptor Blockers on Inflammation
Current Pharmaceutical Design The ONTARGET Trial Programme: Facts and Lessons
Current Hypertension Reviews